Business
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe — — BioCryst to receive $70M upfront, up to $275M in future regulatory and sales milestone payments, and royalties on sales ranging from 18 to 30 percent — — Agreement builds upon prior agreement between the two companies for sale of European ORLADEYO® business to Neopharmed Gentili in 2025 — — Navenibart Phase 3 program in HAE on track for US regulatory filin
About this update from Biocryst Pharmaceuticals, Inc.
[{"type":"image","alt":"BioCryst Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"BioCryst Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/9be0f0f5eacb522c15d80d31bd7eea85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2oMvvMIKvjA9d_E4SRIeSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NA--/https://media.zenfs.com/en/globenewswire.com/9be0f0f5eacb522c15d80d31bd7eea85","width":300,"height":117}},"lazy":false},{"type":"text","content":"— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —","length":139,"tagName":"p"},{"type":"text","content":"— BioCryst to receive $70M upfront, up to $275M in future regulatory and sales milestone payments, and royalties on sales ranging from 18 to 30 percent —","length":153,"tagName":"p"},{"type":"text","content":"— Agreement builds upon prior agreement between the two companies for sale of European ORLADEYO® business to Neopharmed Gentili in 2025 —","length":142,"tagName":"p"},{"type":"text","content":"— Navenibart Phase 3 program in HAE on track for US regulatory filing by end of 2027 —","length":86,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that it entered into a license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema (HAE) in Europe. In exchange, BioCryst will receive $70M upfront and will be eligible to receive up to $275M in future regulatory and sales milestone payments. BioCryst will also receive tiered royalties on net sales ranging from 18% to 30%.","length":527,"tagName":"p"},{"type":"text","content":"Navenibart is an investigational, long-acting plasma kallikrein inhibitor. BioCryst is conducting a Phase 3 clinical program of navenibart in hereditary angioedema. The program is on track to support regulatory filing by the end of 2027.","length":237,"tagName":"p"},{"type":"text","content":"Transaction Rationale","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Builds on an existing relationship with a proven partner with deep regional expertise. Neopharmed G...